Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073593 · ClinicalTrials.gov registry record · Phase 3
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00073593 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 150 participants.
The verdict
NCT00073593, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
Interventions
- DRUG Heparin
- DRUG Bivalirudin
- DRUG Protamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073593
The ClinicalTrials.gov registry entry for NCT00073593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Heparin is the first listed.
NCT00073593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073593 about?
NCT00073593 is a clinical study titled "Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB". The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
What is the current status of trial NCT00073593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00073593?
The interventions under investigation include: Heparin (DRUG), Bivalirudin (DRUG), Protamine (DRUG).
Who is sponsoring clinical trial NCT00073593?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.